JBCHEPHARM Intraday Analysis...


Open 293.40 Change Price %
High 297.10 1 Day -2.75 -0.94
Low 288.10 1 Week 4.70 1.65
Close 289.60 1 Month -33.55 -10.38
Volume 24350 1 Year 12.65 4.57
52 Week High 403.90
52 Week Low 274.00
JBCHEPHARM Important Levels
Resistance 2 297.94
Resistance 1 294.51
Pivot 291.60
Support 1 284.70
Support 2 281.26
NSE INDIA Most Active Stocks
GMRINFRA 18.55 12.42%
JPASSOCIAT 23.50 -1.67%
SINTEX 34.70 2.21%
SUZLON 17.20 -1.71%
GVKPIL 13.25 3.52%
LITL 0.95 5.56%
COALINDIA 246.95 3.78%
HDIL 61.40 -1.92%
BANKBARODA 148.25 0.75%
UNITECH 7.70 -4.35%
NSE INDIA Top Gainers Stocks
SMSLIFE 134.85 52.20%
SPYL 0.25 25.00%
PDUMJEIND 14.80 19.84%
TOKYOPLAST 138.75 19.82%
DOLPHINOFF 92.10 18.23%
GRAVITA 108.95 15.23%
ABAN 185.30 13.58%
MOHOTAMILL 172.60 12.59%
GMRINFRA 18.55 12.42%
SIGNET 9.40 11.90%
NSE INDIA Top Losers Stocks
NAKODA 0.30 -14.29%
PRAKASHSTL 0.35 -12.50%
UVSL 0.40 -11.11%
TULSI 3.40 -9.33%
PRECOT 74.45 -8.26%
SUPREMETEX 3.95 -7.06%
PENPEBS 86.70 -6.37%
PSL 4.00 -5.88%
PSL 4.00 -5.88%
JPOLYINVST 56.45 -5.84%

JB Chemicals & Pharmaceuticals Limited (NSE: JBCHEPHARM)

JBCHEPHARM Technical Analysis 5
As on 17th Aug 2017 JBCHEPHARM Share Price closed @ 289.60 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 341.08 & Strong Sell for SHORT-TERM with Stoploss of 320.88 we also expect STOCK to react on Following IMPORTANT LEVELS.
JBCHEPHARM Target for August
1st Target up-side 329.19
2nd Target up-side 342.72
3rd Target up-side 356.24
1st Target down-side 290.61
2nd Target down-side 277.08
3rd Target down-side 263.56
JBCHEPHARM Synopsis Technicals View
50 Day EMA N/A (Short Term)
100 Day EMA N/A (Mid Term) N/A
200 Day EMA Close is Below EMA 200 (Long Term) Bearish
MACD (12 26 9) N/A N/A
RSI (14) N/A N/A
MFI (14) N/A N/A
CCI (20) N/A N/A
ADX (14) N/A N/A
10 Day Avg Volume N/A
JBCHEPHARM Other Details
Segment EQ
Market Capital 2902640640.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.jbcpl.com
Neelam Centre
4th floor, B Wing
Mumbai, 400030
Phone: 91 22 3045 1200
Fax: 91 22 2493 0534
JB Chemicals & Pharmaceuticals Ltd to consider Q3 results on Feb 4, 2015   Equity Bulls   - 01st Jan 15
Buy JB Chemicals Ltd with a target of Rs 265: Ashwani Gujral   Economic Times   - 19th Aug 14
Buy JB Chemicals; target of Rs 251: Sharekhan   Moneycontrol.com   - 07th Aug 14
JB Chemicals & Pharmaceuticals (₹162.1)   Hindu Business Line   - 17th Jul 14
JB Chemicals settles claims with Cilag GmbH, Q1 Net Sales 24% up   Economic Times   - 27th Jul 13
JB Chemicals launches new division   Hindu Business Line   - 30th Jun 11
JB Chemicals eyes in-licensing route for domestic growth   Business Standard   - 28th May 11
JandJ to buy JB Chem's Russian OTC biz   Business Today   - 24th May 11
High pressure on pharma margins; buy JB Chemicals: Sharekhan   Economic Times   - 18th Feb 11
J B Chemicals & Pharmaceuticals Ltd (JBCPL) Long Term Buy Call: StocksIdea ...   TopNews   - 17th Feb 10
Interactive Technical Analysis Chart JB Chemicals & Pharmaceuticals Limited ( JBCHEPHARM NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on JB Chemicals & Pharmaceuticals Limited
JBCHEPHARM Business Profile
JB Chemicals is in the Pharmaceuticals sector. J B Chemicals & Pharmaceuticals (JBC), flagship company of the Unique group, manufactures basic chemicals, petrochemicals, pharmaceuticals, photographic chemicals and agro-based products. Its product portfolio includes metrogyl, rantac (a ranitidine-based formulation), and nicardia (a cardiac care medicine). The company has 11 manufacturing facilities across four locations. Its APIs include (metronidazole and its intermediates, diclofenac sodium, potassium and other salts of diclofenac and nifedipine), tablets, injectables (SVP and LVP), liquid suspensions, syrups and ointments markets. It has a fully automated 100 per cent EOU lozenges plant (capacity 400 mn units p.a.) at Daman, manufacturing hard catidies. The company plans to increase therapeutic presence in the high growth chronic care segment. Accordingly, it has launched its CMS division and entered into new therapeutic groups such as anti-diabetics, nutritional and urology segments. It has invested Rs 650 million in a new facility at Panoli, India for manufacture of APIs and large/small volume parenterals. The company`s exports contribute 57 per cent to its revenues. JBC created a new SBU called Zephyr to service emerging needs in the neuro-psychiatric and urology segments. The USFDA has accepted the company`s US DMF for Ciprofloxacin Hydrochloride (API). Once approved, JBC will become the third company in India to have both ANDA and DMF approvals for ciprofloxacin. The company plans to continue its R&D efforts in major thrust areas, namely NDDS, natural products and APIs and to further its therapeutic categories of cardiac care, anti-infective, anti-ulcerants and NSAID. It also has plans for R&D including custom synthesis of specialty intermediates. The current market capitalisation stands at Rs 932.25 crore.The company has reported a standalone sales of Rs 253.19 crore and a Net Profit of Rs 33.14 crore for the quarter ended Sep 2013. The company management includes Durga Dass Chopra - Director, Mahesh K Shroff - Director, Bansidhar S Mehta - Director, Bharat P Mehta - Whole Time Director, Shirish B Mody - Whole Time Director, Dinesh B Mody - Whole Time Director, Rajiv C Mody - Director, Niranjan N Maniar - Director, Jyotindra B Mody - Chairman & Managing Director, Kamlesh L Udani - Executive Director, Pranabh Mody - WholeTime Dire. & President, Jashvantrai B Joshi - Director, Sanjay Asher - Alternate Director, Satyanarain Agarwala - Director, Savya Sachi - Director. It is listed on the BSE with a BSE Code of 506943 and the NSE with an NSE Code of JBCHEPHARM. Its Registered office is at Neelam Centre, B Wing 4th Floor,Hind Cycle Road Mumbai,Maharashtra - 400030.